Metabolic reprogramming provides sufficient intermediates and fuels for tumor cell survival and proliferation, which is considered one of the remarkable characteristics of cancer. Tumor cells have various metabolic compartments that are linked by the transfer of diverse catabolites, highlighting the heterogeneous metabolic phenotype of cells within tumors. This metabolic flexibility and variability enable tumor cells to meet the elevated biosynthetic and bioenergetic requirements as well as to maintain a redox balance. Accumulating evidence has revealed that microbiota imbalance contributes to immune microenvironment disorders and digestive diseases, which may ultimately trigger the initiation and progression of gastrointestinal cancers. Notably, microbiota-derived metabolites play an important role in cancer development and the response to treatment, including radiotherapy, chemotherapy, and immunotherapy. However, the detailed mechanisms underlying microbiota homeostasis and metabolic reprogramming in cancer development and digestive diseases remain largely unclear.
The goal of this Research Topic is to provide comprehensive insights into the metabolic plasticity and host-microbiota interactions in the initiation and progression of cancers and digestive diseases. Considering that the metabolic phenotype and microbial niche are heterogeneous among individuals, we encourage investigators to utilize integrated high-throughput technologies (including single-cell and spatial transcriptome, 16S ribosomal RNA sequencing, proteomics, and metabolomics) to reveal novel biomarkers and mechanisms during the development of cancers and digestive diseases. This Research Topic aims to establish valuable and personalized therapeutic strategies and assess the potential clinical application.
We welcome the submission of Original Research articles, Reviews, and Mini reviews. The scope of this Research Topic includes, but is not limited to, the following aspects:
1. The dynamic and spatio-temporal landscape of microbiome in digestive diseases.
2. The relationship between microbiota disorders and metabolic alterations in tumor microenvironment.
3. The novel mechanisms of microbiota-derived metabolites on the development of digestive diseases.
4. Identification of potential therapeutic strategies for targeting metabolism-related signaling by bioactive compounds.
5. Catabolites-driven post-translational modification during cancer progression.
Keywords:
Cancer, Digestive diseases, Metabolism, Microbiota, Therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Metabolic reprogramming provides sufficient intermediates and fuels for tumor cell survival and proliferation, which is considered one of the remarkable characteristics of cancer. Tumor cells have various metabolic compartments that are linked by the transfer of diverse catabolites, highlighting the heterogeneous metabolic phenotype of cells within tumors. This metabolic flexibility and variability enable tumor cells to meet the elevated biosynthetic and bioenergetic requirements as well as to maintain a redox balance. Accumulating evidence has revealed that microbiota imbalance contributes to immune microenvironment disorders and digestive diseases, which may ultimately trigger the initiation and progression of gastrointestinal cancers. Notably, microbiota-derived metabolites play an important role in cancer development and the response to treatment, including radiotherapy, chemotherapy, and immunotherapy. However, the detailed mechanisms underlying microbiota homeostasis and metabolic reprogramming in cancer development and digestive diseases remain largely unclear.
The goal of this Research Topic is to provide comprehensive insights into the metabolic plasticity and host-microbiota interactions in the initiation and progression of cancers and digestive diseases. Considering that the metabolic phenotype and microbial niche are heterogeneous among individuals, we encourage investigators to utilize integrated high-throughput technologies (including single-cell and spatial transcriptome, 16S ribosomal RNA sequencing, proteomics, and metabolomics) to reveal novel biomarkers and mechanisms during the development of cancers and digestive diseases. This Research Topic aims to establish valuable and personalized therapeutic strategies and assess the potential clinical application.
We welcome the submission of Original Research articles, Reviews, and Mini reviews. The scope of this Research Topic includes, but is not limited to, the following aspects:
1. The dynamic and spatio-temporal landscape of microbiome in digestive diseases.
2. The relationship between microbiota disorders and metabolic alterations in tumor microenvironment.
3. The novel mechanisms of microbiota-derived metabolites on the development of digestive diseases.
4. Identification of potential therapeutic strategies for targeting metabolism-related signaling by bioactive compounds.
5. Catabolites-driven post-translational modification during cancer progression.
Keywords:
Cancer, Digestive diseases, Metabolism, Microbiota, Therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.